A phase II trial of oral 4'demethoxydaunorubicin in advanced colorectal carcinoma.
4'Demethoxydaunorubicin (DMDR), an orally active daunorubicin analogue, was administered to 22 patients with advanced colorectal carcinoma. Patients were stratified into good- and poor-risk categories and received doses of 45 mg/m2 and 40 mg/m2, respectively, at 28-day intervals. Twenty-one patients were evaluable for response. No tumour responses occurred, although six patients had stable disease. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 45% of patients. Marrow toxicity was common and usually mild. DMDR appears to have no useful activity in colorectal carcinoma.
Presgrave
P
P
Department of Clinical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.
Woods
R
R
Dalley
D
D
Bell
D
D
Levi
J
J
D000284:Administration, Oral; D000368:Aged; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged
D015255:Idarubicin